Menu Search
Equities

Bristol-Myers Squibb Co

BMY:NYQ

Bristol-Myers Squibb Co

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)49.79
  • Today's Change0.655 / 1.33%
  • Shares traded3.64m
  • 1 Year change-15.66%
  • Beta0.4591
Data delayed at least 15 minutes, as of Sep 16 2024 18:20 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy2
Outperform5
Hold17
Sell3
Strong Sell0

Share price forecast in USD

The 21 analysts offering 12 month price targets for Bristol-Myers Squibb Co have a median target of 51.00, with a high estimate of 75.00 and a low estimate of 33.10. The median estimate represents a 3.81% increase from the last price of 49.13.
High52.7%75.00
Med3.8%51.00
Low-32.6%33.10

Dividends in USD

In 2023, Bristol-Myers Squibb Co reported a dividend of 2.28 USD, which represents a 5.56% increase over last year. The 12 analysts covering the company expect dividends of 2.40 USD for the upcoming fiscal year, an increase of 5.13%.
Div growth (TTM)5.56%
More ▼

Earnings history & estimates in USD

On Jul 26, 2024, Bristol-Myers Squibb Co reported 2nd quarter 2024 earnings of 2.07 per share. This result exceeded the 1.63 consensus of the 17 analysts covering the company and exceeded last year's 2nd quarter results by 18.29%.
The next earnings announcement is expected on Oct 31, 2024.
Average growth rate-0.36%
Bristol-Myers Squibb Co reported annual 2023 earnings of 7.51 per share on Feb 02, 2024.
Average growth rate+13.50%
More ▼

Revenue history & estimates in USD

Bristol-Myers Squibb Company had 2nd quarter 2024 revenues of 12.20bn. This bettered the 11.55bn consensus of the 18 analysts covering the company. This was 7.62% above the prior year's 2nd quarter results.
Average growth rate+2.14%
Bristol-Myers Squibb Company had revenues for the full year 2023 of 45.01bn. This was 2.50% below the prior year's results.
Average growth rate+17.18%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.